Advertisement

Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy

Abstract

Aims and background

Bladder preservation is a treatment option in muscle-invasive bladder carcinoma. The most investigated approach is a trimodality schedule including maximum transurethral resection of bladder tumor (TURBT) followed by chemoradiotherapy. Our aim was to evaluate the use of bladder preservation by radiation oncologists of the Lombardy region in Italy.

Methods and Study design

A survey with 13 items regarding data of 2012 was sent to all 32 radiotherapy centers within the collaboration between the Lombardy Oncological Network and the Lombardy Section of the Italian Society of Oncological Radiotherapy.

Results

Thirteen centers (41%) answered the survey; the presented data come from 11 active centers. In these centers, 11,748 patients were treated with external-beam radiotherapy in 2012, 100 of whom having bladder cancer (0.9%). 74/100 patients received radiotherapy as palliative treatment for T, N or M lesions. A further 9 and 5 patients received radiotherapy for oligometastatic disease (ablative doses to small volumes) and postoperatively, respectively. Bladder preservation was performed in 12 cases and included trimodality and other strategies (mainly TURBT followed by radiotherapy). A multidisciplinary urology tumor board met regularly in 5 of 11 centers. All responders declared their interest in the Lombardy multicenter collaboration on bladder preservation.

Conclusions

Our survey showed that bladder preservation is rarely used in Lombardy despite the availability of the latest radiotherapy technologies and the presence of an urology tumor board in half of the centers. The initiative of multicenter and multidisciplinary collaboration was undertaken to prepare the platform for bladder preservation as a treatment option in selected patients.

Tumori 2015; 101(2): 174 - 178

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/tj.5000235

Authors

Barbara Alicja Jereczek-Fossa, Renzo Colombo, Tiziana Magnani, Cristiana Fodor, Marianna Alessandra Gerardi, Paolo Antognoni, Lucia Barsacchi, Nice Bedini, Stefano Bracelli, Alberto Buffoli, Emanuela Cagna, Gianpiero Catalano, Stefania Gottardo, Corrado Italia, Giovanni Battista Ivaldi, Stefano Masciullo, Anna Merlotti, Enrico Sarti, Marta Scorsetti, Flavia Serafini, Mariasole Toninelli, Elisabetta Vitali, Riccardo Valdagni, Elisa Villa, Dario Zerini, Ottavio De Cobelli, Roberto Orecchia

Article History

Disclosures

Financial support: None
Conflict of interest: None

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • European Institute of Oncology, Milan - Italy
  • University of Milan, Milan - Italy
  • Division of Experimental Oncology, IRCCS, San Raffaele Scientific Institute, Milan - Italy
  • National Cancer Institute, Milan - Italy
  • Insubria University Hospital “Ospedale di Circolo and Macchi Foundation”, Varese - Italy
  • Sant’Anna Hospital, Como - Italy
  • Busto Arsizio Hospital, Busto Arsizio - Italy
  • S. Anna Clinical Institute, San Donato Group, Brescia - Italy
  • IRCCS MultiMedica, Milan - Italy
  • St. Peter’s Polyclinic and St. Mark’s Polyclinic, Ponte S. Pietro-Zingonia - Italy
  • Salvatore Maugeri Foundation, Pavia - Italy
  • Treviglio-Caravaggio Hospital, Treviglio - Italy
  • Humanitas Clinical and Research Center, Rozzano - Italy
  • National Center for Oncological Hadrontherapy CNAO, Pavia - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.